Liposomal formulations in the pharmacological treatment of leishmaniasis: a review

References

• Afrin, F., et al., 2002. Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice. Infection and immunity, 70 (12), 6697–6706.
   PubMed Web of Science ®Google Scholar
• Agrawal, A.K. and Gupta, C.M., 2000. Tuftsin-bearing liposomes in treatment of macrophage-based infections. Advanced drug delivery reviews, 41 (2), 135–146.
   PubMed Web of Science ®Google Scholar
• Agrawal, A.K., et al., 2002. Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters. Journal of drug targeting, 10 (1), 41–45.
   PubMed Web of Science ®Google Scholar
• Ahmad, I., et al., 1991. Tissue distribution and antileishmanial activity of liposomised Amphotericin-B in Balb/c mice. Journal of biosciences, 16 (4), 217–221.
   Web of Science ®Google Scholar
• Allen, T.M. and Cullis, P.R., 2013. Liposomal drug delivery systems: from concept to clinical applications. Advanced drug delivery reviews, 65 (1), 36–48.
   PubMed Web of Science ®Google Scholar
• Al-Mohammed, H.I., Chance, M.L., and Bates, P.A., 2005. Production and characterization of stable amphotericin-resistant amastigotes and promastigotes of Leishmania mexicana. Antimicrobial agents and chemotherapy, 49 (8), 3274–3280.
   PubMed Web of Science ®Google Scholar
• Alvar, J., Croft, S., and Olliaro, P., 2006. Chemotherapy in the treatment and control of leishmaniasis. Advances in parasitology, 61, 223–274.
   PubMed Web of Science ®Google Scholar
• Alving, C.R. and Steck, E.A., 1979. The use of liposome-encapsulated drugs in leishmaniasis. Trends in biochemical sciences, 4, 175–177.
   Web of Science ®Google Scholar
• Alving, C.R., et al., 1978a. Improved therapy of experimental leishmaniasis by use of a liposome-encapsulated antimonial drug. Life sciences, 22 (12), 1021–1026.
   PubMed Web of Science ®Google Scholar
• Alving, C.R., et al., 1978b. Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs. Proceedings of the national academy of sciences of the United States of America, 75 (6), 2959–2963.
   PubMed Web of Science ®Google Scholar
• Alving, C.R., et al., 1980. Liposomes in leishmaniasis: therapeutic effects of antimonial drugs, 8-aminoquinolines, and tetracycline. Life sciences, 26 (26), 2231–2238.
   PubMed Web of Science ®Google Scholar
• Alving, C.R., et al., 1984. Liposomes in leishmaniasis: effects of parasite virulence on treatment of experimental leishmaniasis in hamsters. Annals of tropical medicine and parasitology, 78 (3), 279–286.
   PubMed Web of Science ®Google Scholar
• Amato, V.S., et al., 2004. Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients. Acta tropica, 92 (2), 127–132.
   PubMed Web of Science ®Google Scholar
• Asad, M., et al., 2015. Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOMETM10, a new liposomal amphotericin B. BMC infectious diseases, 15 (1), 188–199.
   PubMed Web of Science ®Google Scholar
• Baillie, A.J., et al., 1986. Non-ionic surfactant vesicles, niosomes, as a delivery system for the anti-leishmanial drug, sodium stibogluconate. Journal of pharmacy and pharmacology, 38 (7), 502–505.
   PubMed Web of Science ®Google Scholar
• Bakker-Woudenberg, I.A.J.M., 1995. Delivery of antimicrobials to infected tissue macrophages. Advanced drug delivery reviews, 17 (1), 5–20.
   Web of Science ®Google Scholar
• Banerjee, G., Bhaduri, A.N., and Basu, M.K., 1994. Mannose-coated liposomal hamycin in the treatment of experimental leishmaniasis in hamsters. Biochemical medicine and metabolic biology, 53 (1), 1–7.
   PubMedGoogle Scholar
• Banerjee, G., et al., 1996. Drug delivery system: targeting of pentamidines to specific sites using sugar grafted liposomes. Journal of antimicrobial chemotherapy, 38 (1), 145–150.
   PubMed Web of Science ®Google Scholar
• Banerjee, G., Medda, S., and Basu, M.K., 1998. A novel peptide-grafted liposomal delivery system targeted to macrophages. Antimicrobial agents and chemotherapy, 42 (2), 348–351.
   PubMed Web of Science ®Google Scholar
• Basu, M.K. and Lala, S., 2004. Macrophage specific drug delivery in experimental leishmaniasis. Current molecular medicine, 4 (6), 681–689.
   PubMed Web of Science ®Google Scholar
• Bawarski, W.E., et al., 2008. Emerging nanopharmaceuticals. Nanomedicine: nanotechnology, biology, and medicine, 4 (4), 273–282.
   PubMed Web of Science ®Google Scholar
• Benvegnu, T., Lemiègre, L., and Cammas-Marion, S., 2009. New generation of liposomes called archaeosomes based on natural or synthetic archaeal lipids as innovative formulations for drug delivery. Recent patents on drug delivery & formulation, 3 (3), 206–220.
   PubMedGoogle Scholar
• Berman, J., 2009. ABLE: a new and improved amphotericin B for visceral leishmaniasis? The American journal of tropical medicine and hygiene, 80 (5), 689–690.
   PubMed Web of Science ®Google Scholar
• Berman, J.D., 1988. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Reviews of infectious diseases, 10 (3), 560–586.
   PubMedGoogle Scholar
• Berman, J.D., et al., 1986. Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrobial agents and chemotherapy, 30 (6), 847–851.
   PubMed Web of Science ®Google Scholar
• Bodhe, P.V., et al., 1999. Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis. Transactions of the royal society of tropical medicine and hygiene, 93 (3), 314–318.
   PubMed Web of Science ®Google Scholar
• Borborema, S.E.T., et al., 2011. Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages. International journal of antimicrobial agents, 38 (4), 341–347.
   PubMed Web of Science ®Google Scholar
• Borborema, S.E.T., et al., 2016. Antimonial drugs entrapped into phosphatidylserine liposomes: physicochemical evaluation and antileishmanial activity. Revista da sociedade brasileira de medicina tropical, 49 (2), 196–203.
   PubMed Web of Science ®Google Scholar
• Bozzuto, G. and Molinari, A., 2015. Liposomes as nanomedical devices. International journal of nanomedicine, 10, 975–999.
   PubMed Web of Science ®Google Scholar
• Bray, P.G., et al., 2003. Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. Trends in parasitology, 19 (5), 232–239.
   PubMed Web of Science ®Google Scholar
• Calderón Gómez, J.E., et al., 2015. Leishmaniasis cutánea verrugosa, éxito terapéutico con anfotericina B de presentación lipídica y miltefosina: reporte de un caso. Piel, 30 (2), 135–137.
   Google Scholar
• Chakravarty, J. and Sundar, S., 2010. Drug resistance in leishmaniasis. Journal of global infectious diseases, 2 (2), 167–176.
   PubMedGoogle Scholar
• Chapman, W.L., et al., 1984. Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog. American journal of veterinary research, 45 (5), 1028–1030.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay, S. and Jafurulla, M., 2011. A novel mechanism for an old drug: amphotericin B in the treatment of visceral leishmaniasis. Biochemical and biophysical research communications, 416 (1–2), 7–12.
   PubMed Web of Science ®Google Scholar
• Cheesman, S., 2000. The topoisomerases of protozoan parasites. Parasitology today (personal ed.), 16 (7), 277–281.
   PubMedGoogle Scholar
• Colhone, M.C., et al., 2015. Nanobiotechnologic approach to a promising vaccine prototype for immunisation against leishmaniasis: a fast and effective method to incorporate GPI-anchored proteins of Leishmania amazonensis into liposomes. Journal of microencapsulation, 32 (2), 143–150.
   PubMed Web of Science ®Google Scholar
• Croft, S.L. and Coombs, G.H., 2003. Leishmaniasis – current chemotherapy and recent advances in the search for novel drugs. Trends in parasitology, 19 (11), 502–508.
   PubMed Web of Science ®Google Scholar
• Croft, S.L. and Olliaro, P., 2011. Leishmaniasis chemotherapy – challenges and opportunities. Clinical microbiology and infection, 17 (10), 1478–1483.
   PubMed Web of Science ®Google Scholar
• Croft, S.L., Seifert, K., and Yardley, V., 2006. Current scenario of drug development for leishmaniasis. The Indian journal of medical research, 123 (3), 399–410.
   PubMed Web of Science ®Google Scholar
• Cruz, A.K., et al., 2009. Current treatment and drug discovery against Leishmania spp. and Plasmodium spp.: a review. Current drug targets, 10 (3), 178–192.
   PubMed Web of Science ®Google Scholar
• Das, A. and Ali, N., 2014. Combining cationic liposomal delivery with MPL-TDM for cysteine protease cocktail vaccination against Leishmania donovani: evidence for antigen synergy and protection. PLoS neglected tropical diseases, 8 (8), e3091.
   PubMed Web of Science ®Google Scholar
• Dasgupta, D., Chakraborty, P., and Basu, M.K., 2000. Ligation of Fc receptor of macrophages stimulates protein kinase C and anti-leishmanial activity. Molecular and cellular biochemistry, 209 (1–2), 1–8.
   PubMed Web of Science ®Google Scholar
• Davidson, R.N., den Boer, M., and Ritmeijer, K., 2009. Paromomycin. Transactions of the royal society of tropical medicine and hygiene, 103 (7), 653–660.
   PubMed Web of Science ®Google Scholar
• Davies, C.R., et al., 2003. Leishmaniasis: new approaches to disease control. BMJ (clinical research ed.), 326 (7385), 377–382.
   PubMed Web of Science ®Google Scholar
• Denton, H., McGregor, J.C., and Coombs, G.H., 2004. Reduction of anti-leishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase, TDR1. Biochemical journal, 381 (2), 405–412.
   PubMed Web of Science ®Google Scholar
• Desjeux, P. and Alvar, J., 2003. Leishmania/HIV co-infections: epidemiology in Europe. Annals of tropical medicine and parasitology, 97 (Suppl 1), 3–15.
   PubMedGoogle Scholar
• Dey, T., et al., 2000. Antileishmanial activities of stearylamine-bearing liposomes. Antimicrobial agents and chemotherapy, 44 (6), 1739–1742.
   PubMed Web of Science ®Google Scholar
• Dutta, M., Bandyopadhyay, R., and Basu, M.K., 1994. Neoglycosylated liposomes as efficient ligands for the evaluation of specific sugar receptors on macrophages in health and in experimental leishmaniasis. Parasitology, 109 (2), 139–147.
   PubMed Web of Science ®Google Scholar
• Ferreira, F.M., et al., 2014. Association of water extract of green propolis and liposomal meglumine antimoniate in the treatment of experimental visceral leishmaniasis. Parasitology research, 113 (2), 533–543.
   PubMed Web of Science ®Google Scholar
• Fong, D., et al., 1994. Paromomycin resistance in Leishmania tropica: lack of correlation with mutation in the small subunit ribosomal RNA gene. The American journal of tropical medicine and hygiene, 51 (6), 758–766.
   PubMed Web of Science ®Google Scholar
• Frézard, F. and Demicheli, F., 2010. New delivery strategies for the old pentavalent antimonial drugs. Expert opinion on drug delivery, 7 (12), 1343–1358.
   PubMed Web of Science ®Google Scholar
• Frézard, F., Demicheli, C., and Ribeiro, R.R., 2009. Pentavalent antimonials: new perspectives for old drugs. Molecules (Basel, Switzerland), 14 (7), 2317–2336.
   PubMed Web of Science ®Google Scholar
• Frézard, F., et al., 2000. Novel methods for the encapsulation of meglumine antimoniate into liposomes. Brazilian journal of medical and biological research, 33 (7), 841–846.
   PubMed Web of Science ®Google Scholar
• Gadelha, E.P.N., et al., 2015. Efficacy and safety of a single dose pentamidine (7 mg/kg) for patients with cutaneous leishmaniasis caused by L. guyanensis: a pilot study. Anais Brasileiros de dermatologia, 90 (6), 807–813.
   PubMed Web of Science ®Google Scholar
• Grant, G. and Bansinath, M., 2001. Liposomal delivery systems for local anesthetics. Regional anesthesia and pain medicine, 26 (1), 61–63.
   PubMed Web of Science ®Google Scholar
• Guru, P.Y., et al., 1989. Drug targeting in Leishmania donovani infections using tuftsin-bearing liposomes as drug vehicles. FEBS letters, 245 (1), 204–208.
   PubMed Web of Science ®Google Scholar
• Hammarton, T.C., Mottram, J.C., and Doerig, C., 2003. The cell cycle of parasitic protozoa: potential for chemotherapeutic exploitation. Progress in cell cycle research, 5, 91–101.
   PubMedGoogle Scholar
• Handler, M.Z., et al., 2015. Cutaneous and mucocutaneous leishmaniasis. Journal of the American academy of dermatology, 73 (6), 911–926.
   PubMed Web of Science ®Google Scholar
• Handman, E., 2001. Leishmaniasis: current status of vaccine development. Clinical microbiology reviews, 14 (2), 229–243.
   PubMed Web of Science ®Google Scholar
• Higa, L.H., et al., 2016. Ultradeformable archaeosomes for needle free nanovaccination with Leishmania braziliensis antigens. PLoS One, 11 (3), e0150185.
   PubMed Web of Science ®Google Scholar
• Hunter, C.A., et al., 1988. Vesicular systems (niosomes and liposomes) for delivery of sodium stibogluconate in experimental murine visceral leishmaniasis. Journal of pharmacy and pharmacology, 40 (3), 161–165.
   PubMed Web of Science ®Google Scholar
• Jain, K. and Jain, N.K., 2013. Novel therapeutic strategies for treatment of visceral leishmaniasis. Drug discovery today, 18 (23–24), 1272–1281.
   PubMed Web of Science ®Google Scholar
• Jhingran, A., et al., 2009. Paromomycin: uptake and resistance in Leishmania donovani. Molecular and biochemical parasitology, 164 (2), 111–117.
   PubMed Web of Science ®Google Scholar
• Kalat, S.A.M., et al., 2014. Experimental parasitology use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice. Experimental parasitology, 143, 5–10.
   PubMed Web of Science ®Google Scholar
• Kandil, E., 1973. Treatment of cutaneous leishmaniasis with trimethoprim-sulfamethoxazole combination. Dermatologica, 146 (5), 303–309.
   PubMedGoogle Scholar
• Kole, L., Das, L., and Das, P.K., 1999. Synergistic effect of interferon-gamma and mannosylated liposome-incorporated doxorubicin in the therapy of experimental visceral leishmaniasis. The journal of infectious diseases, 180 (3), 811–820.
   PubMed Web of Science ®Google Scholar
• Kole, L., et al., 1994. Neoglycoprotein conjugated liposomes as macrophage specific drug carrier in the therapy of leishmaniasis. Biochemical and biophysical research communications, 200 (1), 351–358.
   PubMed Web of Science ®Google Scholar
• Lala, S., et al., 2004. Harmine: evaluation of its antileishmanial properties in various vesicular delivery systems. Journal of drug targeting, 12 (3), 165–175.
   PubMed Web of Science ®Google Scholar
• Lezama-Dávila, C., 1999. Vaccination of C57BL/10 mice against cutaneous Leishmaniasis. Use of purified gp63 encapsulated into niosomes surfactants vesicles: a novel approach. Memórias do instituto oswaldo cruz, 94 (1), 67–70.
   PubMed Web of Science ®Google Scholar
• Lima, M.I.S., et al., 2009. Genotoxic effects of the antileishmanial drug glucantime®. Archives of toxicology, 84 (3), 227–232.
   Web of Science ®Google Scholar
• Lucero, E., et al., 2015. Effectiveness and safety of short course liposomal amphotericin B (AmBisome) as first line treatment for visceral leishmaniasis in Bangladesh. PLoS neglected tropical diseases, 9 (4), e0003699.
   PubMed Web of Science ®Google Scholar
• Machado, P.R.L., et al., 2015. Treatment of disseminated leishmaniasis with liposomal amphotericin B. Clinical infectious diseases, 61 (6), 945–949.
   PubMed Web of Science ®Google Scholar
• Mbongo, N., et al., 1998. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrobial agents and chemotherapy, 42 (2), 352–357.
   PubMed Web of Science ®Google Scholar
• McGwire, B.S., et al., 2014. Leishmaniasis: clinical syndromes and treatment. QJM: monthly journal of the association of physicians, 107 (1), 7–14.
   PubMed Web of Science ®Google Scholar
• Medda, S., Mukhopadhyay, S., and Basu, M.K., 1999. Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal forms. Journal of antimicrobial chemotherapy, 44 (6), 791–794.
   PubMed Web of Science ®Google Scholar
• Minodier, P. and Parola, P., 2007. Cutaneous leishmaniasis treatment. Travel medicine and infectious disease, 5 (3), 150–158.
   PubMedGoogle Scholar
• Minodier, P., et al., 2003. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients. Fundamental and clinical pharmacology, 17, 183–188.
   PubMed Web of Science ®Google Scholar
• Momeni, A., et al., 2013. Development of liposomes loaded with anti-leishmanial drugs for the treatment of cutaneous leishmaniasis. Journal of liposome research, 23 (2), 134–144.
   PubMed Web of Science ®Google Scholar
• Mukherjee, M., Ball, W.B., and Das, P.K., 2014. Leishmania donovani activates SREBP2 to modulate macrophage membrane cholesterol and mitochondrial oxidants for establishment of infection. The international journal of biochemistry & cell biology, 55, 196–208.
   PubMed Web of Science ®Google Scholar
• Murray, H.W., et al., 2005. Advances in leishmaniasis. Lancet (London, England), 366 (9496), 1561–1577.
   PubMed Web of Science ®Google Scholar
• Nandi, G., et al., 1993. Synthesis, spectroscopic properties and antileishmanial activity of pentamidine analogues. Journal of the Indian chemical society, 70, 523.
   Web of Science ®Google Scholar
• New, R.R.C., Chance, M.L., and Heath, S., 1983. Liposome therapy for experimental cutaneous and visceral leishmaniasis. Biology of the cell, 47, 59–64.
   Web of Science ®Google Scholar
• No, J.H., 2016. Visceral leishmaniasis: revisiting current treatments and approaches for future discoveries. Acta tropica, 155, 113–123.
   PubMed Web of Science ®Google Scholar
• Nylén, S. and Gautam, S., 2010. Immunological perspectives of leishmaniasis. Journal of global infectious diseases, 2 (2), 135–146.
   PubMedGoogle Scholar
• Okwor, I. and Uzonna, J., 2016. Social and economic burden of human leishmaniasis. The American journal of tropical medicine and hygiene, 94 (3), 489–493.
   PubMed Web of Science ®Google Scholar
• Owais, M. and Gupta, C.M., 2005. Targeted drug delivery to macrophages in parasitic infections. Current drug delivery, 2 (4), 311–318.
   PubMedGoogle Scholar
• Pal, S., Ravindran, R., and Ali, N., 2004. Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB/c Mice. Antimicrobial agents and chemotherapy, 48 (9), 3591–3593.
   PubMed Web of Science ®Google Scholar
• Papagiannaros, A., et al., 2005. Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations. Biomedicine & pharmacotherapy, 59 (10), 545–550.
   PubMed Web of Science ®Google Scholar
• Pardakhty, A., et al., 2012. Preparation and evaluation of niosomes containing autoclaved Leishmania major: a preliminary study. Journal of microencapsulation, 29 (3), 219–224.
   PubMed Web of Science ®Google Scholar
• Paris, C., et al., 2004. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrobial agents and chemotherapy, 48 (3), 852–859.
   PubMed Web of Science ®Google Scholar
• Pathak, M.K. and Yi, T., 2001. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. The journal of immunology, 167 (6), 3391–3397.
   PubMed Web of Science ®Google Scholar
• Pérez-Victoria, F.J., et al., 2006. Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy, 9 (1–2), 26–39.
   PubMed Web of Science ®Google Scholar
• Peters, W., Evans, D.A., and Lanham, S.M., 1983. Importance of parasite identification in cases of leishmaniasis. Journal of the royal society of medicine, 76 (7), 540–542.
   PubMed Web of Science ®Google Scholar
• Pund, S. and Joshi, A., 2017. Chapter 23 – nanoarchitectures for neglected tropical protozoal diseases: challenges and state of the art. In: A.M. Grumezescu, ed. Nano- and microscale drug delivery systems. Amsterdam: Elsevier, 439–480.
   Google Scholar
• Qi, P., et al., 2016. The biological activity of cationic liposomes in drug delivery and toxicity test in animal models. Environmental toxicology and pharmacology, 47, 159–164.
   PubMed Web of Science ®Google Scholar
• Raay, B., et al., 1999. Targeting of piperine intercalated in mannose-coated liposomes in experimental leishmaniasis. Indian journal of biochemistry & biophysics, 36 (4), 248–251.
   PubMed Web of Science ®Google Scholar
• Ram, V.J. and Nath, M., 1996. Progress in chemotherapy. Current medicinal chemistry, 3, 303–316.
   Web of Science ®Google Scholar
• Renslo, A.R. and McKerrow, J.H., 2006. Drug discovery and development for neglected parasitic diseases. Nature chemical biology, 2 (12), 701–710.
   PubMed Web of Science ®Google Scholar
• Ribeiro, R.R., et al., 2008. Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniate. Antimicrobial agents and chemotherapy, 52 (7), 2564–2572.
   PubMed Web of Science ®Google Scholar
• Rittig, M. and Bogdan, C., 2000. Leishmania-host-cell interaction: complexities and alternative views. Parasitology today (personal ed.), 16 (7), 292–297.
   PubMedGoogle Scholar
• Roberts, C.W., et al., 2003. Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Molecular and biochemical parasitology, 126 (2), 129–142.
   PubMed Web of Science ®Google Scholar
• Romero, G.A.S. and Boelaert, M., 2010. Control of visceral leishmaniasis in Latin America—a systematic review. PLoS neglected tropical diseases, 4 (1), e584.
   PubMed Web of Science ®Google Scholar
• Rongen, H.A., Bult, A., and van Bennekom, W., 1997. Liposomes and immunoassays. Journal of immunological methods, 204 (2), 105–133.
   PubMed Web of Science ®Google Scholar
• Rotureau, B., 2006. Are New World leishmaniases becoming anthroponoses? Medical hypotheses, 67 (5), 1235–1241.
   PubMed Web of Science ®Google Scholar
• Russell, D.G. and Alexander, J., 1988. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes. Journal of immunology, 140 (4), 1274–1279.
   PubMed Web of Science ®Google Scholar
• Saha, A.K., Mukherjee, T., and Bhaduri, A., 1986. Mechanism of action of amphotericin B on Leishmania donovani promastigotes. Molecular and biochemical parasitology, 19 (3), 195–200.
   PubMed Web of Science ®Google Scholar
• Samad, A., Sultana, Y., and Aqil, M., 2007. Liposomal drug delivery systems: an update review. Current drug delivery, 4 (4), 297–305.
   PubMedGoogle Scholar
• Sands, M., Kron, M.A., and Brown, R.B., 1985. Pentamidine: a review. Reviews of infectious diseases, 7 (5), 625–634.
   PubMedGoogle Scholar
• Schettini, D.A., et al., 2003. Distribution of liposome-encapsulated antimony in dogs. Brazilian journal of medical and biological research, 36 (2), 269–272.
   PubMed Web of Science ®Google Scholar
• Schettini, D.A., et al., 2005. Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate. Brazilian journal of medical and biological research, 38 (12), 1879–1883.
   PubMed Web of Science ®Google Scholar
• Schettini, D.A., et al., 2006. Improved targeting of antimony to the bone marrow of dogs using liposomes of reduced size. International journal of pharmaceutics, 315 (1–2), 140–147.
   PubMed Web of Science ®Google Scholar
• Shahian, M. and Alborzi, A., 2009. Effect of meglumine antimoniate on the pancreas during treatment of visceral leishmaniasis in children. International medical journal of experimental and clinical research, 15 (6), CR290–CR293.
   Google Scholar
• Shimizu, Y., et al., 2003. Protection against Leishmania major infection by oligomannose-coated liposomes. Bioorganic & medicinal chemistry, 11 (7), 1191–1195.
   PubMed Web of Science ®Google Scholar
• Sindermann, H., et al., 2004. Miltefosine (Impavido): the first oral treatment against leishmaniasis. Medical microbiology and immunology, 193 (4), 173–180.
   PubMed Web of Science ®Google Scholar
• Singh, N., Kumar, M., and Singh, R.K., 2012. Leishmaniasis: current status of available drugs and new potential drug targets. Asian pacific journal of tropical medicine, 5 (6), 485–497.
   PubMed Web of Science ®Google Scholar
• Sinha, R., et al., 2015. Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani. Antimicrobial agents and chemotherapy, 59 (1), 344–355.
   PubMed Web of Science ®Google Scholar
• Srivastava, S., et al., 2016. Possibilities and challenges for developing a successful vaccine for leishmaniasis. Parasites & vectors, 9 (1), 277.
   PubMed Web of Science ®Google Scholar
• Stone, N.R.H., et al., 2016. Liposomal Amphotercin B (Ambisome®): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs, 76 (4), 485–500.
   PubMed Web of Science ®Google Scholar
• Sundar, S. and Chakravarty, J., 2010. Liposomal amphotericin B and leishmaniasis: dose and response. Journal of global infectious diseases, 2 (2), 159–166.
   PubMedGoogle Scholar
• Sundar, S. and Olliaro, P.L., 2007. Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management. Therapeutics and clinical risk management, 3 (5), 733–740.
   PubMedGoogle Scholar
• Sundar, S., et al., 2011. Ambisome plus miltefosine for Indian patients with kala-azar. Transactions of the royal society of tropical medicine and hygiene, 105 (2), 115–117.
   PubMed Web of Science ®Google Scholar
• Sundar, S., et al., 2015. Single-dose indigenous liposomal amphotericin B in the treatment of Indian visceral leishmaniasis: a phase 2 study. The American journal of tropical medicine and hygiene, 92 (3), 513–517.
   PubMed Web of Science ®Google Scholar
• Tempone, A.G. and Andrade, H.F.d.A., 2008. Nanoformulações de antimônio pentavalente encapsuladas em lipossomos contendo fosfatidilserina demonstram maior eficácia contra Leishmaniose Visceral experimental. Revista do instituto Adolfo Lutz, 67, 131–136.
   Google Scholar
• Tempone, A.G., et al., 2004. Targeting Leishmania (L.) chagasi amastigotes through macrophage scavenger receptors: the use of drugs entrapped in liposomes containing phosphatidylserine. The journal of antimicrobial chemotherapy, 54 (1), 60–68.
   PubMed Web of Science ®Google Scholar
• Thakur, A., Kaur, H., and Kaur, S., 2015. Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis. Parasitology international, 64 (1), 70–78.
   PubMed Web of Science ®Google Scholar
• Toledo-Machado, C.M., et al., 2015. Use of phage display technology in development of canine visceral leishmaniasis vaccine using synthetic peptide trapped in sphingomyelin/cholesterol liposomes. Parasites & vectors, 8, 133.
   PubMed Web of Science ®Google Scholar
• Torchilin, V., 2012. Liposomes in drug delivery. In: Fundamentals and applications of controlled release drug delivery. Boston (MA): Springer US, 289–328.
   Google Scholar
• Trouiller, P., et al., 2002. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet, 359 (9324), 2188–2194.
   PubMed Web of Science ®Google Scholar
• Unger, C., et al., 1989. Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo. Acta oncologica, 28 (2), 213–217.
   PubMed Web of Science ®Google Scholar
• Valladares, J.E., et al., 1997. Pharmacokinetics of liposome-encapsulated meglumine antimonate after intramuscular and subcutaneous administration in dogs. The American journal of tropical medicine and hygiene, 57 (4), 403–406.
   PubMed Web of Science ®Google Scholar
• Valladares, J.E., et al., 2001. Long term improvement in the treatment of canine leishmaniosis using an antimony liposomal formulation. Veterinary parasitology, 97 (1), 15–21.
   PubMed Web of Science ®Google Scholar
• van Griensven, J. and Boelaert, M., 2011. Combination therapy for visceral leishmaniasis. Lancet (London, England), 377 (9764), 443–444.
   PubMed Web of Science ®Google Scholar
• Wadhone, P., et al., 2009. Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response. Journal of immunology (Baltimore, MD: 1950), 182 (11), 7146–7154.
   PubMed Web of Science ®Google Scholar
• Weldon, J.S., et al., 1983. Liposomal chemotherapy in visceral leishmaniasis: an ultrastructural study of an intracellular pathway. Zeitschrift für parasitenkunde parasitology research, 69 (4), 415–424.
   PubMed Web of Science ®Google Scholar
• Wyllie, S., Cunningham, M.L., and Fairlamb, A.H., 2004. Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. Journal of biological chemistry, 279 (38), 39925–39932.
   PubMed Web of Science ®Google Scholar
• Yardley, V. and Croft, S.L., 2000. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. International journal of antimicrobial agents, 13 (4), 243–248.
   PubMed Web of Science ®Google Scholar
• Zaghloul, I.Y. and Al-Jasser, M., 2004. Effect of renal impairment on the pharmacokinetics of antimony in hamsters. Annals of tropical medicine and parasitology, 98 (8), 793–800.
   PubMed Web of Science ®Google Scholar
• Zielinska, J., et al., 2016. Thermodynamics and kinetics of amphotericin B self-association in aqueous solution characterized in molecular detail. Scientific reports, 6, 19109.
   PubMed Web of Science ®Google Scholar